Colorectal cancer diagnosed before the usual screening age
Official title: Early-Onset Colorectal Cancer Patients Too Young for Screening: Outcomes and Treatment Patterns
Run by Methodist Health System · NCT07559825 · Data updated 2026-11-12
This study uses national cancer registries to see if people diagnosed with colorectal cancer before age 35 present with more advanced disease but live longer than older patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 35 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Methodist Health System Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Status | Recruiting |
| Started | January 31, 2020 |
| Main results expected | January 2027 |
| Study ends | January 2028 |
| Registry record updated | April 30, 2026 |
| Trial ID | NCT07559825 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People with a confirmed diagnosis of colorectal cancer, particularly those diagnosed before age 35, are the focus of this analysis.
✕Probably not a fit
People without colorectal cancer will not directly benefit from this registry analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This population-based retrospective analysis uses the SEER registry and the National Cancer Data Base to compare patients diagnosed with colorectal cancer before age 35 to those diagnosed at older ages. Investigators will examine stage at presentation, insurance status at diagnosis, treatment patterns by stage, and cancer-specific survival adjusted for relevant covariates. The hypothesis is that younger patients present with more advanced disease but have longer survival because they receive more aggressive therapy. Results are derived from registry records and statistical analyses rather than prospective patient visits.
Why it matters
Potential benefit: If differences by age are confirmed, the findings could help inform screening recommendations and guide treatment planning for younger patients with colorectal cancer.
How similar studies have gone: Prior registry-based studies have documented rising incidence and distinct features of early-onset colorectal cancer, so this comparative registry approach is established though specific age-focused outcomes remain an active area of research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Colorectal cancer Exclusion Criteria: * No Colorectal cancer
Where it's running
-
Methodist Dallas Medical Center- Clinical Research Institute
Dallas, Texas, United States Recruiting
Study contacts
- Principal investigator: Rohan Jeyarajah, MD — Methodist Health System
- Study coordinator: Crystee Cooper, DHEd
- Email: ClinicalResearch@mhd.com
- Phone: 214-947-1280
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.